Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent compared to Abbott s XIENCE PRIME™. These results were presented in a late-breaking clinical trials session at the EuroPCR congress in Paris by principal investigator, Prof. Stephan Windecker, MD of University Hospital Bern, Switzerland.
Las personas mayores que sufren de un tipo de arritmia cardiaca conocida como fibrilación auricular también podrían ser más propensas a experimentar declives mentales antes, sugiere un estudio reciente.
Abbott Vascular has announced the publication of two European post approval studies for its transcatheter device, MitraClip, for mitral regurgitation. ACCESS-EU, which was published in the Journal of American College of Cardiology, and the Transcatheter mitral valve interventions (TRAMI) registry, which was published in EuroIntervention, both show positive outcomes for the device.
Biosensors has entered into a licensing agreement with Eurocor for its drug-eluting balloon technology and related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, Biosensors will market and sell, under its own brand, drug-eluting balloons manufactured by Eurocor.
A substudy of the BIOFLOW-II trial, presented as a late-breaking trial at EuroPCR (21–24 May, Paris, France), showed that Biotronik’s drug-eluting stent with a biodegradable polymer (Orsiro) was non-inferior to a drug-eluting stent with a durable polymer (Xience Prime, Abbott Vascular) in terms of in-stent late lumen loss at nine months.
CID released the results of Demonstr8 randomised trial results at a late-breaking trials session at EuroPCR (21–24 May, Paris, France). The study, presented by principal investigator Francesco Prati, showed that the Cre8 drug-eluting stent was non-inferior to a bare metal stent with a high statistically significant difference (RUTTS Score <30%; 99.75% CRE8™ vs.99.55% BMS; p<0.0001).
According to a study presented at EuroPCR EuroPCR (21–24 May, Paris, France), the use of the Axxess drug-eluting stent for the treatment of complex coronary bifurcation lesions resulted in low levels of both major adverse cardiovascular events (MACE) and very late definite stent thrombosis over a five-year period.
Neovasc, at EuroPCR (21–24 May, Paris, France), reported initial data from open-label patient registries that are tracking the progress of refractory angina patients implanted with its Reducer device, which is a percutaneous device that is CE marked for the treatment of refractory angina.
OrbusNeich has announced that it has received the CE mark for its dual therapy coronary stent (Combo), and that it has launched the device in Europe and markets in Asia Pacific and Middle East Regions.
Las personas que toman dosis altas de unos analgésicos comunes conocidos como antiinflamatorios no esteroides (AINE) se enfrentan a un mayor riesgo de sufrir de problemas del corazón, muestra un análisis reciente.
Volcano announced preliminary results from the ADVISE (Adenosine vasodilator independent stenosis evaluation) II trial at a hotline late-breaking clinical trial session at EuroPCR (21–24 May, Paris, France). These prospective results confirm prior retrospective publications and demonstrate the clinical usefulness of an iFR/FFR hybrid approach to simplify lesion assessment and to save the use of hyperaemic drugs in a significant number of patients.
At EuroPCR 2013 in Paris, France (21–24 May), three separate analyses have addressed one of the most common clinical challenges in the treatment of complex coronary artery disease and showed that the the Resolute drug-eluting stent from Medtronic has performed strongly in coronary bifurcation lesions over the long term.
OrbusNeich today launched the world s first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The introduction of the COMBO Stent is in conjunction with the company s receipt of a CE Mark for the product and involves a sales roll-out in Europe and selected markets in the Asia Pacific and Middle East regions.
OrbusNeich has announced that its Genous stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents in low-risk no stent thrombosis segment elevation acute coronary syndrome patients at six months. Data from JACK-EPC, an investigator-initiated randomised study, were published in Minerva Cardioangiologica.
On the 22 May 2013 at EuroPCR in Paris, France, Direct Flow Medical, a transcatheter heart valve company focused on improving patient outcomes, announced that it had met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE mark trial by achieving 99% freedom from all-cause mortality at 30 days.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos